Immunic advances ‘potentially groundbreaking' MS therapy vidofludimus calcium during Q1
- Immunic Inc (NASDAQ:IMUX) continued to advance its clinical programs for its lead drug asset, nuclear receptor related 1 (Nurr1) activator vidofludimus calcium (IMU-838), during the first quarter of 2024. CEO Daniel Vitt highlighted progress in the company's Phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and the twin Phase 3 ENSURE trials in relapsing multiple sclerosis (RMS) for its “potentially groundbreaking” therapy vidofludimus calcium.
- 05/08/2024
|
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
- – Substantially Bolstered Balance Sheet Through a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – – Received Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis; Multilayered Intellectual Property Strategy Provides Protection Into 2041 in the United States – – Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Remain Underway – – Webcast to be Held Today, May 8, 2024, at 8:00 am ET – NEW YORK , May 8, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. "During the first quarter and subsequent period, we have continued to advance both the phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and the twin phase 3 ENSURE trials in relapsing multiple sclerosis (RMS), for our potentially groundbreaking, orally available lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838)," stated Daniel Vitt, Ph.D.
- 05/08/2024
|
Immunic to Participate in Investor and Scientific Conferences in May
- NEW YORK , May 6, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May: May 12-14 and 21-22: Bio€quity Europe 2024. Jessica Breu, Vice President Investor Relations and Communications at Immunic, will attend and host one-on-one investor meetings at this conference taking place in San Sebastián, Spain and virtually.
- 05/06/2024
|
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
- – Webcast to be Held at 8:00 am ET on May 8, 2024 – NEW YORK , May 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the first quarter ended March 31, 2024, including a corporate update, on Wednesday, May 8, 2024, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.
- 05/01/2024
|
Immunic publishes extended data from Phase 2 MS trial in peer-reviewed journal
- Immunic Inc (NASDAQ:IMUX) has published extended data from its Phase 2 EMPhASIS trial of its lead asset vidofludimus calcium in relapsing-remitting Multiple Sclerosis (RRMS) in the peer-reviewed journal Neurology, Neuroimmunology and Neuroinflammation, an official journal of the American Academy of Neurology. Immunic is developing its small molecule investigational drug vidofludimus calcium as an oral treatment option for patients with MS and other chronic inflammatory and autoimmune diseases.
- 04/30/2024
|
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
- – 30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Compared to Pooled Placebo at 24 Weeks – – Improvements in Serum Neurofilament Light Chain Consistent with Recently Announced Interim Phase 2 CALLIPER Data in Progressive Multiple Sclerosis – – Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Remain Underway – NEW YORK , April 30, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that data from its phase 2 EMPhASIS trial of lead asset, vidofludimus calcium (IMU-838), in patients with relapsing-remitting multiple sclerosis (RRMS) has been published online on April 25, 2024 in Neurology® Neuroimmunology & Neuroinflammation, an official journal of the American Academy of Neurology. The paper, lead authored by coordinating investigator, Robert J.
- 04/30/2024
|
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
- NEW YORK , April 4, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following investor conferences in April: April 9: Immunic's MS R&D Day . Management of Immunic, including Daniel Vitt, Ph.D.
- 04/04/2024
|
Immunic granted patent for specific polymorph of vidofludimus calcium in US
- Immunic Inc (NASDAQ:IMUX) has received a Notice of Allowance for a composition-of-matter patent covering a specific polymorph of vidofludimus calcium, which is being advanced as a treatment for chronic inflammatory and autoimmune diseases, particularly multiple sclerosis. The patent, titled "Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents", solidifies the company's intellectual property protection around its lead, late-stage asset.
- 03/20/2024
|
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
- – Patent Will Also Cover a Related Method of Production of the Material – – Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis – – Multilayered Intellectual Property Strategy Provides Protection Into 2041 in the United States and Into 2039 Internationally, Unless Extended Further – NEW YORK, March 20, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 16/981,122, entitled, "Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents," covering the composition-of-matter of a specific polymorph of vidofludimus calcium (IMU-838) and a related method of production of the material. The claims are expected to provide protection into 2039, unless extended further.
- 03/20/2024
|
Immunic to Participate in Investor and Scientific Conferences in March
- NEW YORK , March 7, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in March: March 11-13: Leerink Partners Global Biopharma Conference . Daniel Vitt, Ph.D.
- 03/07/2024
|
Immunic to present data for lead asset vidofludimus calcium from Phase 2 MS and COVID-19 trials
- Immunic Inc (NASDAQ:IMUX) announced that it will present data from its Phase 2 CALLIPER and CALVID-1 clinical trials of its lead asset vidofludimus calcium (IMU-838) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024. "Having two poster presentations on our lead asset, vidofludimus calcium, at the prestigious ACTRIMS Forum is a testament to the strength of the data we have generated," Immunic CEO Dr. Daniel Vitt said in a statement.
- 02/29/2024
|
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
- NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data from the company's phase 2 CALLIPER and CALVID-1 clinical trials of lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in two poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024, taking place from February 29 to March 2, in West Palm Beach, FL. "Having two poster presentations on our lead asset, vidofludimus calcium, at the prestigious ACTRIMS Forum is a testament to the strength of the data we have generated," stated Daniel Vitt, Ph.D.
- 02/29/2024
|
Immunic expects financial stability through 2025 as MS clinical programs advance
- Biotechnology company Immunic Inc (NASDAQ:IMUX) disclosed its financial results for the fourth quarter and year ended December 31, 2023, alongside significant clinical advancements, marking a pivotal year for the firm. Immunic CEO Daniel Vitt lauded the company's strides in 2023, citing the successful completion of a three-tranche private placement worth up to $240 million.
- 02/22/2024
|
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
- – Significantly Strengthened Balance Sheet in January 2024 with Execution of Three-Tranche Private Placement of up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025 Based on Initial $80 Million Tranche – – Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis, Consistent Across the Entire Progressive Multiple Sclerosis Population and All Subtypes; Top-Line CALLIPER Data Expected in April 2025 – – Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing – – Expanded Vidofludimus Calcium Patent Portfolio with Additional New Patents Granted; Exclusivity Protection Expected Into 2041 in the United States, Unless Extended Further – – Webcast to be Held Today, February 22, 2024, at 8:00 am ET – NEW YORK , Feb. 22, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update. "Immunic made remarkable progress throughout 2023, and these achievements were punctuated by the successful three-tranche private placement of up to $240 million, which we announced last month.
- 02/22/2024
|
Immunic's cutting-edge MS treatment approach: insights from CEO Dr Daniel Vitt
- The journey toward effective therapies for patients with multiple sclerosis (MS) is marked by persistent challenges. Despite advancements in addressing relapses, the specter of disability progression looms large, leaving a significant unmet need in patient care.
- 02/15/2024
|
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
- – Webcast to be Held at 8:00 am ET on February 22, 2024 – NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the fourth quarter and year ended December 31, 2023, including a corporate update, on Thursday, February 22, 2024, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.
- 02/15/2024
|
Immunic CSO highlights her role ahead of International Day of Women and Girls in Science
- Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof sheds light on her crucial role and the groundbreaking strides being made in the scientific world ahead of the International Day of Women and Girls in Science on 11 February. As CSO, Kohlhof is pivotal in crafting the scientific strategy for Immunic's projects, focusing on understanding molecular actions, ensuring safety in preclinical regulatory work, and developing biomarkers for early activity indications.
- 02/09/2024
|
Immunic to Participate in Investor and Scientific Conferences in February
- NEW YORK , Feb. 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February: February 8: BioCapital Europe 2024 . Daniel Vitt, Ph.D.
- 02/01/2024
|
Immunic announces up to $240M financing
- Immunic Inc (NASDAQ:IMUX) shares took off after the biotechnology firm announced it would be raising up to $240 million in a private placement. Immunic stock was up 11.2% at US$1.58 before Friday's opening bell.
- 01/05/2024
|
Immunic gets patent notice of allowance for lead asset to treat multiple sclerosis
- Immunic, Inc. said the US Patent and Trademark Office has given it a notice of allowance for patent application 17/992,162 entitled entitled 'Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases'. The patent covers dosing regimens associated with the company's lead asset, vidofludimus calcium and other salt forms as well as free acid forms for the treatment of multiple sclerosis, providing protection into 2038.
- 11/21/2023
|
Immunic, Inc. (IMUX) Q3 2023 Earnings Call Transcript
- Immunic, Inc. (NASDAQ:IMUX ) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Jessica Breu - Head of IR & Communications Dr. Daniel Vitt - CEO and President Glenn Whaley - CFO Conference Call Participants Caroline Pocher - Wedbush PacGrow Liam Hiester - Piper Sandler Matt Kaplan - Ladenberg Thalmann Tom Smith - Leerink Partners William Wood - B. Riley Jessica Breu Good morning, and welcome to Immunic's Third Quarter 2023 Earnings Call.
- 11/14/2023
|
Immunic advances drug targeting progressive multiple sclerosis during 3Q
- Immunic Inc (NASDAQ:IMUX) – a biotechnology company developing a pipeline of orally administered small molecule therapies for chronic inflammatory and autoimmune diseases - during the three months ending in September advanced its lead drug asset, a nuclear receptor-related 1 (Nurr1) activator vidofludimus calcium IMU-838. Immunic exited the third quarter with cash, cash equivalents and investments of $59.7 million which it said it expects will fund its operations into September of 2024.
- 11/14/2023
|
Immunic gets Notice of Allowance for US patent protecting treatment of relapsing MS with vidofludimus and salts
- Immunic Inc (NASDAQ:IMUX) told investors it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application protecting the treatment of relapsing multiple sclerosis (RMS). The company said in a statement that patent application 17/391,442, entitled, "Treatment of Multiple Sclerosis Comprising DHODH Inhibitors," covers a daily dose of about 10 mg to 45 mg of vidofludimus calcium (IMU-838) and other salts as well as free acid forms for the treatment of RMS.
- 11/02/2023
|
Immunic presents data from Phase 2 study of vidofludimus calcium in relapsing-remitting MS
- Immunic Inc (NASDAQ:IMUX) announced that data from its Phase 2 EMPhASIS trial of nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in relapsing-remitting multiple sclerosis (RRMS) has been presented at MSMilan 2023, the 9th Joint ECTRIMS-ACTRIMS Meeting by Dr. Robert Fox.
- 10/11/2023
|
Immunic shares soar 48% after-hours buoyed by interim MS data
- Shares in Immunic Therapeutics Inc. soared 48% in after-hours trading following the release of encouraging interim data from its phase II CALLIPER trial assessing the potential of its treatment for progressive multiple sclerosis (PMS).
- 10/10/2023
|
Immunic to Participate in Industry and Investor Conferences in September
- NEW YORK , Sept. 6, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in September: September 13-14: BioPharm America™.
- 09/06/2023
|
Immunic completes enrollment in trial of vidofludimus calcium in patients with progressive MS
- Immunic Inc (NASDAQ:IMUX) said it has completed the enrollment of its phase 2 CALLIPER trial of lead asset vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS). A total of 467 patients with primary MS or active or non-active secondary MS have been randomized to either 45mg of vidofludimus calcium or placebo.
- 08/17/2023
|
Immunic reports 2Q results; expects to be able to fund operations into 4Q 2024
- Immunic, Inc. said that at the end of its second quarter to June 30, 2023, it had cash, cash equivalents and investments of $77.3 million with which it expects to be able to fund its operations into the fourth quarter of 2024. "During the second quarter, we reported important clinical and preclinical data from our two, lead pipeline programs, including the most advanced drug candidate, vidofludimus calcium (IMU-838), as well as IMU-856," Daniel Vitt, CEO and President of Immunic, said in a statement.
- 08/03/2023
|
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
- – Webcast to be Held at 8:00 am ET on August 3, 2023 – NEW YORK , July 27, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the second quarter ended June 30, 2023, including a corporate update, on Thursday, August 3, 2023, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.
- 07/27/2023
|
Immunic to Participate in Scientific and Investor Conferences in July
- NEW YORK , June 29, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in July: July 6-8: Symposium 234: Mucosal Immunology – A Translational View into the Clinic. Martina Wirth, Ph.D.
- 06/29/2023
|
Immunic has a blockbuster clinical pipeline to treat multiple sclerosis and gastrointestinal diseases
- New York-based biotechnology company Immunic Inc (NASDAQ:IMUX) has one or more potential blockbusters in its clinical pipeline. The firm's promising lead asset vidofludimus calcium (IMU-838) is an oral drug in Phase 3 clinical trials for patients with multiple sclerosis (MS), a disabling neurological condition caused by the immune system attacking the protective layer around nerve cells, triggering dizziness, muscle atrophy and vision loss.
- 06/16/2023
|
US stocks set to open higher on possible resolution to debt ceiling debacle
- 7:55am: Deal or no deal? Wall Street is likely to open in the green as traders return from the Memorial Day long weekend to news that US President Joe Biden and House Speaker Kevin McCarthy reached a final agreement on Sunday to raise the country's debt ceiling, now at $31 trillion.
- 05/30/2023
|
Immunic to Participate in Scientific and Investor Conferences in June
- NEW YORK , May 30, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June: May 31-June 3: Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023. Robert J. Fox, MD, Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, will present data from the open-label extension part of Immunic's phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838) in relapsing-remitting multiple sclerosis at this conference in Aurora, Colorado.
- 05/30/2023
|
Immunic notes neuroprotective potential of vidofludimus calcium highlighted in preclinical data
- Immunic Inc (NASDAQ:IMUX) has announced the publication of preclinical data highlighting the neuroprotective potential of its investigational drug, vidofludimus calcium (IMU-838). The data confirms that vidofludimus calcium acts as a potent activator of the nuclear receptor-related 1 (Nurr1), in addition to its known function as a dihydroorotate dehydrogenase (DHODH) inhibitor.
- 05/17/2023
|
Immunic, Inc. (IMUX) Q1 2023 Earnings Call Transcript
- Immunic, Inc. (NASDAQ:IMUX ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Jessica Breu - Head of Investor Relations & Communications Daniel Vitt - Chief Executive officer, President & Director Glenn Whaley - Chief Financial Officer Conference Call Participants Andreas Argyrides - Wedbush Matt Kaplan - Ladenburg Tom Smith - SVB Securities Jessica Breu Good morning, and welcome to Immunic's First Quarter 2023 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.
- 05/14/2023
|
Immunic stock rises following corporate update of clinical program progress
- Immunic shares are higher Thursday after the company announced its results for the first quarter ended March 31 and issued a corporate update. "In the first quarter of 2023, we reported outstanding results from two key clinical programs.
- 05/11/2023
|
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update
- – Webcast to be Held at 8:00 am ET on May 11, 2023 – NEW YORK , May 9, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the first quarter ended March 31, 2023, including a corporate update, on Thursday, May 11, 2023, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.
- 05/09/2023
|
Immunic presents data showing beneficial effects of IMU-856 on gut health at Digestive Disease Week 2023
- Immunic Inc (NASDAQ:IMUX) said it has presented new clinical and pre-clinical data on the molecule IMU-856 at Digestive Disease Week (DDW) 2023 currently underway in Chicago. The presentation includes data on how IMU-856 has been shown to have a beneficial effect on gut health by helping to modulate, stabilize and enhance expression of the Sirtuin 6 (SIRT6) protein in the gastrointestinal tract.
- 05/08/2023
|
Immunic reports positive results from part C of phase 1 clinical trial of IMU-856 in patients with celiac disease
- Immunic Inc (NASDAQ:IMUX) said the results from the part C portion of its phase 1 clinical trial of IMU-856 in patients with celiac disease are positive, providing what the company believes as initial clinical proof-of-concept for an entirely new therapeutic approach to gastrointestinal disorders. The data showed that there was protection of gut architecture and reduction of gluten-induced intestinal damage, improvement of the symptoms related to gluten exposure experienced by patients, dose-dependent changes in biomarker responses and the enhancement of nutrient absorption.
- 05/04/2023
|
Immunic Inc announces appointment of Dr Richard Rudick to board of directors
- Immunic Inc (NASDAQ:IMUX) has announced the appointment of Dr Richard Rudick to its board of directors, effective April 26, 2023. The biotechnology company developing small molecule therapies for chronic inflammatory and autoimmune diseases noted that Dr Rudick is a thought leader in multiple sclerosis with decades of experience in the clinic, academia, and industry.
- 04/27/2023
|
Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data
- Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.
- 04/06/2023
|
Immunic's positive trial data for IMU-838 impresses analysts
- Immunic has caught the attention of market analysts with the release of positive data from the maintenance phase of its Phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC). The company on Wednesday said data from the maintenance phase of CALDOSE-1 showed a dose-linear increase in clinical remission as compared to the placebo at week 50.
- 04/06/2023
|
Why Is Immunic (IMUX) Stock Up 23% Today?
- Immunic (NASDAQ: IMUX ) stock is getting a boost on Wednesday after the company released results from its Phase 2 CALDOSE-1 Trial. This study had it testing the effectiveness of vidofludimus calcium as a treatment for moderate-to-severe ulcerative colitis (UC).
- 04/05/2023
|
Immunic reports positive data from maintenance phase of Phase 2 CALDOSE-1 trial
- Immunic Inc (NASDAQ:IMUX) has announced positive data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC). The company said data from the maintenance phase of CALDOSE-1 showed a dose-linear increase in clinical remission as compared to the placebo at week 50.
- 04/05/2023
|
Best Penny Stocks For 2023? 3 To Watch In March
- Hot penny stocks to watch now. The post Best Penny Stocks For 2023?
- 03/06/2023
|
Immunic, Inc. (IMUX) Q4 2022 Earnings Call Transcript
- Immunic, Inc. (NASDAQ:IMUX ) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Jessica Breu - Head, IR & Communications Daniel Vitt - CEO, President & Director Glenn Whaley - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co. Matthew Kaplan - Ladenburg Thalmann & Co. Andreas Argyrides - Wedbush Securities William Wood - B. Riley Securities Jessica Breu Good morning and welcome to Immunic's Fourth Quarter and Year End 2022 Earnings Call.
- 02/23/2023
|
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
- – Webcast to be Held at 8:00 am ET on February 23, 2023 – NEW YORK , Feb. 16, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the fourth quarter and year ended December 31, 2022, including a corporate update, on Thursday, February 23, 2023, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.
- 02/16/2023
|
Immunic: Multiple Sclerosis Data In H2 2023 Could Provide Major Shift
- Interim results from the phase 2 CALLIPER study using IMU-838 for treatment of patients with Progressive MS are expected in the 2nd half of 2023; topline results are end of 2024. Final results from the phase 3 ENSURE study, using IMU-838 for the treatment of patients with relapsing multiple sclerosis, are expected by the end of 2025.
- 02/07/2023
|
Immunic to Participate in Scientific and Investor Conferences in February
- NEW YORK , Jan. 25, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in February: February 1-2: 31st Pharmacovigilance 2023 . Darius-Jean Namdjou, Ph.D.
- 01/25/2023
|
Immunic, Inc. (IMUX) Q3 2022 Earnings Call Transcript
- Immunic, Inc. (NASDAQ:IMUX ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Jessica Breu - Head, IR and Communications Daniel Vitt - CEO and President Glenn Whaley - CFO Andreas Muehler - Chief Medical Officer Conference Call Participants Andreas Argyrides - Wedbush Yasmeen Rahimi - Piper Sandler Matt Kaplan - Ladenburg Operator Jessica Breu Good morning, everyone, and welcome to Immunic's Third Quarter 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.
- 11/06/2022
|
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
- – Webcast to be Held at 8:00 am ET on November 3, 2022 – NEW YORK , Oct. 27, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2022, including a corporate update, on Thursday, November 3, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.
- 10/27/2022
|
Steven Cohen's Firm Boosts Stakes in Relmada and Immunic
- Steven Cohen (Trades, Portfolio), chairman and CEO of Point72 Asset Management, disclosed in regulatory filings that his firm established a position in Progress Acquistion Corp. ( PGRWU , Financial) and boosted its holdings of Relmada Therapeutics Inc. ( RLMD , Financial) and Immunic Inc. ( IMUX , Financial).
- 10/25/2022
|
Why Is Immunic (IMUX) Stock Down 76% Today?
- Immunic (NASDAQ: IMUX ) stock is plummeting on Friday after the company reported a high placebo rate in a Phase 1b clinical trial. This trial is currently ongoing and is testing the effectiveness of IMU-935 in patients with moderate-to-severe psoriasis.
- 10/21/2022
|
Immunic: New MS Drugs Need Extreme Product Differentiation
- The MS market is highly saturated. Although there's a lot of lacunae, new MS drugs need to show exactly why they should exist.
- 10/12/2022
|
Immunic, Inc. to Participate in Investor Conferences in September
- NEW YORK , Sept. 1, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor conferences in September: September 7-8: Citi's 17th Annual BioPharma Conference.
- 09/01/2022
|
Immunic, Inc. (IMUX) CEO Daniel Vitt on Q2 2022 Results - Earnings Call Transcript
- Immunic, Inc. (NASDAQ:IMUX ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Jessica Breu - Head, Investor Relations and Communications Daniel Vitt - Chief Executive Officer and President Glenn Whaley - Chief Financial Officer Hella Kohlhof - Chief Scientific Officer Conference Call Participants Andreas Argyrides - Wedbush Yasmeen Rahimi - Piper Sandler Matt Kaplan - Ladenburg Michael Kratky - SVB Securities Jessica Breu Good morning, everybody and welcome to Immunic's Second Quarter 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.
- 08/06/2022
|
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update
- – Webcast to be Held at 8:00 am ET on August 4, 2022 – NEW YORK , July 28, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the second quarter ended June 30, 2022, including a corporate update, on Thursday, August 4, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.
- 07/28/2022
|
Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June
- NEW YORK , June 8, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, industry and investor conferences in June: June 10-13: 13th International Congress on Autoimmunity. Evelyn Peelen, Ph.D.
- 06/08/2022
|
Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails
- Immunic's (IMUX) phase II CALDOSE-1 study, evaluating vidofludimus calcium in patients with moderate-to-severe ulcerative colitis, fails to meet primary endpoint. Stock down.
- 06/03/2022
|
Why is Immunic (IMUX) Stock Plunging 40% Today?
- Immunic (IMUX) stock is falling hard on Thursday after the company released poor results from a recent Phase 2 clinical trial. The post Why is Immunic (IMUX) Stock Plunging 40% Today?
- 06/02/2022
|
Immunic Inc. (IMUX) CEO Daniel Vitt on Q1 2022 Results - Earnings Call Transcript
- Immunic Inc. (NASDAQ:IMUX ) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Daniel Vitt – Chief Executive officer, President & Director Glenn Whaley – Vice President of Finance and Principal Financial & Accounting Officer Conference Call Participants Thomas Smith – SVB Leerink Yasmeen Rahimi – Piper Sandler Andreas Argyrides – Wedbush Matthew Kaplan – Lautenbach Tallmann Boobalan Pachaiyappan – H.C. Wainwright Zegbeh Jallah – Roth Capital Operator Good morning and welcome to Immunic's First Quarter 2022 Earnings Call.
- 05/10/2022
|
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update
- – Webcast to be Held at 8:00 am ET on May 10, 2022 – NEW YORK, May 3, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the first quarter ended March 31, 2022, including a corporate update, on Tuesday, May 10, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.
- 05/03/2022
|
Immunic Inc. (IMUX) CEO Daniel Vitt on Q4 2021 Results - Earnings Call Transcript
- Immunic Inc. (IMUX) CEO Daniel Vitt on Q4 2021 Results - Earnings Call Transcript
- 02/24/2022
|
Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis
- NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that Evelyn Peelen, Ph.D., Senior Manager Translational Pharmacology at Immunic, will present preclinical data on the potent anti-inflammatory activity of vidofludimus calcium (IMU-838), the company's selective oral DHODH inhibitor, at the 17th Congress of European Crohn's and Colitis Organization (ECCO).
- 02/18/2022
|
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update
- NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the fourth quarter and year ended December 31, 2021, including a corporate update, on Thursday, February 24, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.
- 02/17/2022
|
Is Immunic (IMUX) Stock Outpacing Its Medical Peers This Year?
- Here is how Immunic (IMUX) and Owens & Minor (OMI) have performed compared to their sector so far this year.
- 01/21/2022
|
Can Immunic (IMUX) Climb 357% to Reach the Level Wall Street Analysts Expect?
- The consensus price target hints at a 357.4% upside potential for Immunic (IMUX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 01/11/2022
|
Immunic, Inc. (IMUX) CEO Daniel Vitt on Q3 2021 Results - Earnings Call Transcript
- Immunic, Inc. (IMUX) CEO Daniel Vitt on Q3 2021 Results - Earnings Call Transcript
- 11/06/2021
|
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2021 and Provide Corporate Update
- NEW YORK, Nov. 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2021, including a corporate update, on Thursday, November 4, 2021, before market open. A webcast will follow at 8:00 am ET.
- 11/01/2021
|
Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer
- NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today. In this newly created role, Mr.
- 10/14/2021
|
Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis
- NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced enrollment of the first patient in its phase 2 CALLIPER trial of lead asset IMU-838, the company's selective oral DHODH inhibitor, in patients with progressive multiple sclerosis (PMS).
- 09/30/2021
|
Immunic, Inc. to Participate in Scientific and Investor Conferences in October
- NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in October: October 6-7: B &T Cell-Mediated Autoimmune Disease Drug Development Summit.
- 09/28/2021
|
Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19
- NEW YORK and GOETTINGEN, Germany, Sept. 22, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the execution of an in-license agreement with the University Medical Center Goettingen, Germany, covering the combination of DHODH inhibitors and nucleoside analogues to treat viral infections (COVID-19 and Influenza).
- 09/22/2021
|
Immunic, Inc. to Participate in Investor and Scientific Conferences in September
- NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in September: September 13-15: H.C.
- 09/08/2021
|
Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity
- NEW YORK, Aug. 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the second quarter ended June 30, 2021 and highlighted recent activity. "So far this year, we have made outstanding progress with both our selective oral DHODH inhibitor, IMU-838, as well as IMU-935, a highly potent and selective inverse agonist of the transcription factor RORγt, enabling what we believe will be an eventful and potentially transformative first half of 2022.
- 08/06/2021
|
Immunic, Inc. to Participate in Investor Conferences in August
- NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor conferences in August: August 9-10: BTIG Virtual Biotechnology Conference 2021. Daniel Vitt, Ph.D.
- 08/03/2021
|
Immunic, Inc. Announces Closing of $45.0 Million Public Offering
- NEW YORK, July 19, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $10.00 per share. The Company received total proceeds from the offering, before deducting the underwriting discounts and other offering expenses, of $45.0 million.
- 07/19/2021
|
Why Immunic Plummeted by 21% on Thursday
- Word of a new share issue made investors feel queasy.
- 07/15/2021
|
Immunic Stock Is Trading Lower After Equity Raise Of $45M To Fund Lead Pipeline Candidates
- Immunic Inc (NASDAQ: IMUX) has priced an underwritten public offering of 4.5 million shares at $10 per share, representing a discount of about 16% from the last close price of $11.89 on Wednesday. The gross proceeds are expected to be approximately $45 million.
- 07/15/2021
|
IMUX Stock Falls Over 20% Pre-Market: Why It Happened
- The stock price of Immunic Inc (NASDAQ: IMUX) fell by over 20% pre-market. This is why it happened.
- 07/15/2021
|
Immunic, Inc. Announces Proposed Public Offering of Common Stock
- NEW YORK, July 14, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All the shares to be sold in the offering will be offered by the Company.
- 07/14/2021
|
Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist
- NEW YORK, July 12, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced that it will host a virtual R&D Day today at 4:00 pm ET. Immunic's management and Zuoming Sun, Ph.D.
- 07/12/2021
|
Immunic Stock Jumps As FDA Signs Off On 2 Clinical Trial Applications
- The FDA has signed off Immunic Inc's (NASDAQ: IMUX) investigational new drug application for the Phase 3 ENSURE program of lead asset IMU-838 in patients with relapsing-remitting multiple sclerosis. In addition, the FDA also gave a green signal to the company's separate IND application for the supportive Phase 2 CALLIPER trial of IMU-838 in patients with progressive multiple sclerosis (PMS).
- 07/01/2021
|
IMUX Stock Price Increases Over 5% Pre-Market: Why It Happened
- The stock price of Immunic, Inc. (NASDAQ: IMUX) increased by over 5% pre-market. These are the details.
- 07/01/2021
|
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis
- NEW YORK, July 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for the phase 3 ENSURE program of lead asset IMU-838, the company's selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis (RRMS). In addition, the FDA also cleared the company's separate IND application for the supportive phase 2 CALLIPER trial of IMU-838 in patients with progressive multiple sclerosis (PMS).
- 07/01/2021
|
Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July
- NEW YORK, June 28, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, industry and investor conferences in July: June 30-July 3: The International Federation of Psoriasis Association's 6th World Psoriasis & Psoriatic Arthritis Conference 2021. Dr. Thomas M Polasek, Clinical Pharmacology Registrar, Royal Adelaide Hospital, Australia, will present the first clinical experience with IMU-935, an orally available, selective inverse agonist of RORγt.
- 06/28/2021
|
Immunic, Inc. to Participate in Industry and Investor Conferences in June
- NEW YORK, June 10, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in June: June 14-18: BIO Digital (formerly BIO International Convention). Members of the company's business development team will host one-on-one partnering meetings during the conference.
- 06/10/2021
|
Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel
- NEW YORK, June 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the appointment of Inderpal Singh as General Counsel, effective today. In his new role, Mr.
- 06/01/2021
|
Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity
- NEW YORK, May 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended March 31, 2021 and highlighted recent activity. "Our clinical program activities have continued unabated, with significant progress having recently been achieved for our lead asset, selective oral DHODH inhibitor, IMU-838," stated Daniel Vitt, Ph.D.
- 05/06/2021
|
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection
- NEW YORK, April 15, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced interim data from Cohort 2 of its phase 2 EMPhASIS trial of IMU-838 in relapsing-remitting multiple sclerosis (RRMS). Immunic has concluded from this data, along with previously published data from Cohort 1, that 30 mg once daily IMU-838 is the most appropriate dose for future phase 3 trials in patients with RRMS.
- 04/15/2021
|
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
- NEW YORK, April 13, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, investor and industry conferences in April: April 17-22: 2021 Virtual American Academy of Neurology (AAN) Annual Meeting. Robert J.
- 04/13/2021
|
Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838
- NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE Prime Standard: VSC), today announced the signing of an agreement under which Immunic will settle its remaining obligation of a 4.4% royalty on net sales of selective oral DHODH inhibitor, IMU-838, for $17.25 million. The transaction will be payable 50% in cash and 50% in shares of Immunic's common stock.
- 03/31/2021
|
Immunic Gets Bullish Rating On Multiple Sclerosis Drug Prospect
- Immunic Inc's (NASDAQ: IMUX) lead candidate, IMU-838, has an “attractive safety profile” and exhibited positive efficacy results in the Phase II trials, according to JMP Securities. The Immunic Analyst: Gobind Singh initiated coverage of Immunic with a Market Outperform rating and a price target of $55.
- 03/24/2021
|
7 Beaten Down Stocks With Insider Buying
- A simple yet effective way to screen stocks for investment ideas is to look at what the insiders are doing, and to keep an eye out for insider buying. The insiders are the people in a company who have access to confidential information that could move the price of their company's stock.
- 03/23/2021
|
Immunic, Inc. to Participate in Industry and Investor Conferences in March
- NEW YORK, March 2, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management's participation in the...
- 03/02/2021
|
Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity
- NEW YORK, Feb. 26, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced financial results for the year...
- 02/26/2021
|
Immunic's IMU-838 Shows Promising Clinical Effect In Mid-Stage Liver Disease Study
- Immunic Inc (NASDAQ: IMUX) has announced top-line data from an investigator-sponsored Phase 2 proof-of-concept trial evaluating IMU-838 in primary sclerosing cholangitis (PSC), a rare liver disease characterized by inflamed and narrow bile ducts, thus preventing bile from flowing correctly. 27.3% of the patients in the per-protocol population had a clinically relevant reduction of serum alkaline phosphatase higher than 25% at week 24, without an increase in liver biochemistry of more than 33%, as compared to baseline.
- 02/18/2021
|
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
- NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced positive top-line data from an...
- 02/18/2021
|
IMU-838 Data In COVID-19 Study Fails To Cheer Immunic Investors; Stock Tanks
- Immunic Inc (NASDAQ: IMUX) completes the main analysis of Phase 1 CALVID-1 trial evaluating its lead asset, IMU-838. It is a selective oral DHODH inhibitor used in hospitalized patients with moderate COVID-19.
- 02/17/2021
|
Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
- NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that its lead asset, IMU-838, the...
- 02/17/2021
|
Immunic, Inc. to Participate in Investor Conferences in January
- NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management's participation in the...
- 01/05/2021
|
Immunic, Inc. Added to NASDAQ Biotechnology Index
- NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it has been selected for...
- 12/14/2020
|
Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board
- NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the formation of a...
- 11/17/2020
|
Immunic, Inc. to Participate in Investor and Scientific Conferences in November
- NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management's participation in the...
- 11/10/2020
|
Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed
- NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that the company has enrolled and...
- 11/02/2020
|
Global Automotive Inertial Measurement Units Sensors Market to reach USD 6.77 billion by 2024, Continental AG and Honeywell International Inc. Emerge as Key Contributors to Growth | Technavio
- The Global Automotive Inertial Measurement Unit Sensors Market will grow by USD 6.77 bn during 2020-2024
- 10/14/2020
|
The Daily Biotech Pulse: CureVac Close To Coronavirus Vaccine Deal With EU, Entera Bio's Positive Readout, Patent Protection For Co-Diagnostics
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
- 08/20/2020
|
Immunic : Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters' Option to Purchase Additional Shares | MarketScreener
|
Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters' Option to Purchase Additional Shares
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 5,750,000 shares of its common stock at a public offering price of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 750,000 shares.
- 08/10/2020
|
Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.00 per share. The proceeds of the offering to the Company are expected to be $90.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
- 08/05/2020
|
Immunic Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:IMUX)
- Immunic announced positive top line data for IMU-838. Catalyst Pharma gets stung in FDA lawsuit.
- 08/04/2020
|
Latest Generation YellowScan Mapping Systems Rely on Velodyne Lidar Sensors to Meet Demanding Needs of Survey Professionals
- Velodyne Lidar announced YellowScan systems use Velodyne’s lidar sensors to help achieve the high precision and accuracy needed in aerial 3D mapping.
- 08/04/2020
|
Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it intends to offer and sell 5 million shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters an option for 30 days to purchase up to an additional 750,000 shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
- 08/03/2020
|
Immunic Spikes 35% In Pre-Market On Positive Multiple Sclerosis Data
- Immunic (IMUX) has announced positive top-line data from its phase 2 EMPhASIS trial of lead asset, IMU-838, the company’s selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis (RRMS). Shares are now spiking 35% in Monday’s pre-market trading.The study achieved all primary and key secondary endpoints, indicating activity in RRMS patients.In particular, the study met its primary endpoint, demonstrating a statistically significant reduction in the cumulative number of combined unique active (CUA) magnetic resonance imaging (MRI) lesions up to week 24 in patients receiving 45mg of IMU-838 once daily, by 62% (p=0.0002), as compared to placebo.The study also met its key secondary endpoint, showing a statistically significant reduction in the cumulative number of CUA MRI lesions for the 30mg once daily dose, by 70% (p<0.0001), as compared to placebo.All other secondary endpoints, including those based on other MRI parameters and on clinical endpoints such as relapse events, also provided a noticeable signal and numerical benefit for the IMU-838 treatment groups, as compared to placebo.Moreover, administration of IMU-838 was observed to be safe and well-tolerated with a 42.9% rate of treatment-emergent adverse events vs 43.5% for placebo. Likewise, serious treatment-emergent adverse events were only observed in 3 out of 140 IMU-838-treated patients, and in 1 out of 69 patients on placebo.The phase 2 EMPhASIS trial was an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group study, designed to assess the efficacy and safety of IMU-838 in patients with RRMS. Of the 210 patients randomized in 36 centers, 209 patients received at least one dose of IMU-838 or placebo, and 197 patients completed the blinded 24-week treatment period.“Given the strength of these top-line results, we will continue to prepare a clinical phase 3 program for IMU-838 in RRMS and, after a full review of the data, anticipate providing a further update on development strategy” commented Daniel Vitt, CEO of Immunic.“We are also looking forward to reading out clinical data from the other ongoing phase 2 trials of IMU-838 in COVID-19, primary sclerosing cholangitis and ulcerative colitis in the upcoming months” he added.Meanwhile the company announced a net loss for the three months ended June 30, 2020 of $11.5 million, or $0.90 per basic and diluted share.Shares in Immunic have exploded by 77% year-to-date, and analysts have a unanimously bullish outlook on the stock. The Strong Buy Street consensus comes with a $48 average analyst price target, indicating significant further upside potential lies ahead.According to HC Wainwright analyst Ram Selvaraju the positive top-line data of IMU-838 in RRMS could facilitate a transformative out-licensing deal. For the analyst the next key upcoming catalyst is potential interim clinical data from the CALVID-1 trial, proving the impact of IMU-838 in attenuating viral load in COVID-19-infected patients. (See IMUX stock analysis on TipRanks).Related News: GW Pharma Scores New FDA Approval For CBD Drug Epidiolex Incyte, MorphoSys Win FDA Nod For ‘Key Revenue Driver’ Tafasitamab Moderna Could Charge $50-$60 Per Covid-19 Vaccine Course- Report More recent articles from Smarter Analyst: * Eli Lilly Kicks Off Covid-19 Antibody Trial In Nursing Home Residents * Nordex To Sell Wind, Solar Projects To RWE For $474 Million * Nio July Car Deliveries Spike 322%; Shares Up 6% In Pre-Market * Varian Pops 24% In Pre-Market On $16.4B Buyout Deal; BTIG Sticks To Buy
- 08/03/2020
|
Immunic : Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
|
Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced positive top-line data from its phase 2 EMPhASIS trial of lead asset, IMU-838, the company's selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis (RRMS). The study achieved all primary and key secondary endpoints, indicating activity in RRMS patients. In particular, the study met its primary endpoint, demonstrating a statistically significant reduction in the cumulative number of combined unique active (CUA) magnetic resonance imaging (MRI) lesions up to week 24 in patients receiving 45mg of IMU-838 once daily, by 62% (p=0.0002), as compared to placebo. The study also met its key secondary endpoint, showing a statistically significant reduction in the cumulative number of CUA MRI lesions for the 30mg once daily dose, by 70% (p<0.0001), as compared to placebo.
- 08/02/2020
|
Deep Learning for Inertial Navigation
- A short review of cutting edge deep learning-based solutions for inertial navigation.
- 08/01/2020
|
The Daily Biotech Pulse: Sanofi-GSK Land $2.1B Funding For Coronavirus Vaccine, D-Day For GW Pharma, FDA Nod For Roche
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 30)
Achieve Life Sciences Inc (NASDAQ: ACHV)
Annexon Inc (NASDAQ: ANNX) (IPOed July 24)
Atossa Therapeutics...
- 07/31/2020
|
Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it will report financial results for the second quarter ended June 30, 2020, and provide a corporate update on Monday, August 3, 2020 before the opening of the U.S. financial markets.
- 07/30/2020
|
Immunic: A 'Deep Dive' On A Lottery Ticket
- Immunic Inc. recently received the go ahead from the FDA for a Covid-19 trial evaluating its anti-inflammatory and autoimmune candidate, IMU-838.
- 07/27/2020
|
Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced enrollment of the first patients in an investigator-sponsored phase 2 clinical trial of the company's selective oral DHODH inhibitor, IMU-838, for the treatment of patients with coronavirus disease 2019 (COVID-19). The IONIC trial is a prospective, randomized, parallel-group, open-label phase 2b study, designed to evaluate efficacy and safety of IMU-838 in combination with the neuraminidase inhibitor, Oseltamivir (Tamiflu®), in approximately 120 adult patients with moderate-to-severe COVID-19.
- 07/27/2020
|
The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 22)
ABIOMED, Inc. (NASDAQ: ABMD)
Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO)
Bio-Rad Laboratories,...
- 07/23/2020
|
Honda Africa Twin Adventure Sports: an all-round performer
- Honda’s Africa Twin is a giant among motorcycles, often recognised even by those with little interest in bikes, thanks to its victories in the famous Paris-Dakar race - and its paint-job that virtually pokes your eyes out. Resplendent in red white and blue and distinguished in some versions by its gold-coloured wheels and front forks, it’s also a real showboat thanks also to its imposing height and intrepid stance.
- 07/17/2020
|
Antivirals In The COVID-19 Space
- A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.
- 07/13/2020
|
Global Military GNSS Anti-Jamming Systems Market 2020-2025: Focus on Component, Element Number, Platform and Region - ResearchAndMarkets.com
|
COVID-19 Impact and Recovery Analysis- Automotive Inertial Measurement Unit Sensors Market 2020-2024 | The Strong Demand For IMU Sensors From Automotive to Boost Growth | Technavio
- The Global automotive inertial measurement unit sensors market will grow by $ 6.77 bn during 2020-2024
- 07/06/2020
|
3 “Strong Buy” Micro-Cap Stocks That Offer Attractive Returns
- If you are looking to hit a home run in the stock market, the NASDAQ Composite is a good place to start. The index is home to surging technology, internet, and biotech stocks. Despite the adverse effects from COVID-19, the index is up 25% over the past year, and recently hit a new all-time high. Now comes the hard part. How are investors supposed to determine which stocks are poised to take off? Will the current winners continue climbing, or will new high-flyers emerge? Finding the next big one is challenging to say the least. On top of this, there are numerous and sometimes conflicting investing strategies to consider. Bearing this in mind, Wall Street analysts can provide some inspiration. The experts possess extensive knowledge about the stocks they cover, and offer insights on compelling names that don’t always get the same attention as other heavyweights. To this end, we used TipRanks’ database to pinpoint three micro-cap stocks that have earned a “Strong Buy” consensus rating from the analyst community. Not to mention each boasts excellent upside potential. We’re talking about over 120% here. Immunic, Inc. (IMUX) The first stock on our list is New York-based Immunic, a pharmaceutical company developing drugs to treat chronic autoimmune, inflammatory and viral diseases, with its market cap landing at only $182.9 million. The company’s lead prospect is IMU-838, an orally-dosed DHODH (an enzyme in humans that is encoded by the DHODH gene on chromosome 16) inhibitor. IMU-838 is currently being tested in four Phase 2 studies for multiple indications including COVID-19. Other promising drugs that Immunic is developing include IMU-935, a treatment for autoimmune diseases and MU-856, a treatment for gastrointestinal disorders. On June 15, Immunic announced that the first patients in its Phase 2 CALVID-1 clinical trial of IMU-838 in COVID-19 had been dosed. Ladenburg Thalmann analyst Matthew Kaplan explained, “The CALVID-1 study is a prospective, multicenter (10-35 centers in Germany, USA, and half a dozen European countries), randomized, placebo-controlled, double-blind Phase 2 clinical trial in approximately 230 patients with moderate COVID-19, and will evaluate efficacy, safety, and tolerability of IMU-838.” The development marked an important milestone in advancing the candidate. Commenting on this, Kaplan stated, “An interim analysis is planned after 200 patients have completed treatment, which could lead to an expansion to a confirmatory Phase 3 trial with an adaptive trial design…We are encouraged by the preclinical data and clinical plan and look forward to future updates.” Speaking to the strength of Immunic’s other possible catalysts, Kaplan noted, “We also believe the earlier stage pipeline programs (IMU-935 and IMU-856) provide for significant additional potential upside.” Based on all of the above, Kaplan reiterated his Buy recommendation. He also has a $50 price target on the stock, which indicates significant upside potential of 307%. (To watch Kaplan’s track record, click here) All in all, other analysts agree with Kaplan. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Meanwhile, the $51 average price target, which is more aggressive than Kaplan’s, represents a huge 315% potential increase from the share price of $12.30. (See Immunic stock analysis on TipRanks) Benefytt Technologies, Inc. (BFYT) Next up we have Benefytt Technologies, (previously called Health Insurance Innovations, Inc.) which sells a range of Medicare-related health insurance plans as well as other health and life insurance products. Last year, management made a strategic shift towards targeting Medicare dollars rather than individual and family plans. Consequently, the company, which has a market cap of $310.8 million, is navigating its way through a transition year, negatively affecting its operating performance. In the first quarter of 2020, revenue fell to $71.6 million, from $87.3 million in the prior-year quarter. That said, a closer look at the results reveals a bright spot. Revenue from Benefytt’s Medicare segment, which is new to the company since June 2019, came in at $18.9 million. Management plans to grow the Medicare segment to between $190 million to $210 million in the coming year. Five-star analyst from Cantor Fitzgerald, Steven Halper, shares the company’s optimistic view. “We continue to believe the company is taking the necessary steps to grow its Medicare business. It still expects 2020 Medicare revenue to be $190-210 million,” he commented. Pointing to Benefytt’s stock price, the five-star analyst said, “We have made some modest changes to our estimates but our price target remains at $75. Either way, we believe the shares are compelling at current levels.” To this end, Halper has an Overweight (i.e. Buy) rating on the stock. His $75 price target suggests hefty upside potential of 244%. (To watch Halper’s track record, click here) Turning to the rest of the Street, other analysts are on the same page. 5 Buys and no Holds or Sells have been issued in the last three months, so BFYT gets a Strong Buy consensus rating. The average price target is $47.30, which implies sizable upside potential of 117%. (See Benefytt stock analysis on TipRanks) Scorpio Bulkers (SALT) Last but not least is Scorpio Bulkers, an international shipping company that provides marine transportation for dry bulk commodities such as coal, grains, and fertilizers. At $181.1 million, its market cap is the smallest on our list. It has been a trying period for Scorpio Bulkers shareholders. The company’s shares have significantly underperformed the broader market, plunging 76% year-to-date, compared to a 3% loss for the S&P; 500. Nevertheless, BTIG analyst Gregory Lewis believes the stock is ripe for a bounce. In a recent research report, he noted, “The company has prepared itself for the enacted IMO 2020 fuel regulation by installing scrubbers on its fleet which should provide above market earnings and a way for investors to capture dislocations in the marine bunker fuel market.” Further adding to the analyst’s bullish sentiment, Lewis sees several upcoming catalysts that are set to bolster shipping rates and profitability. These include countries reopening their economies and undertaking a restocking cycle, and governments employing stimulus programs to jump-start their economies. In line with his optimistic take, Lewis rates the stock a Buy and maintains a $40 price target, which translates to substantial upside potential of 164%. (To watch Lewis’ track record, click here) Do other analysts on the Street agree with Lewis? Yes, they do. The consensus rating is a Strong Buy, based on 5 Buys and 1 Hold. The average price target of $34.17 implies meaningful upside potential of 126%. (See Scorpio Bulkers stock analysis on TipRanks)
- 07/05/2020
|
Stocks To Watch: Postmates, Walgreens And Cannabis Plays
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 07/04/2020
|
Imu, sconto del 20% per chi sceglie l’addebito in conto
- Imu, sconto del 20% per chi sceglie l’addebito in conto
- 07/02/2020
|
KVH Launches New Inertial Sensor with Photonic Integrated Chip Technology | MarketScreener
|
Short & Caught: The ASX small caps investors are shorting right now - Stockhead
- Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by selling stocks you do not actually own in the hope of buying them back at a lower price. Because shorting is restricted under Australian law, any substantial shorting of stocks …
- 06/29/2020
|
ImmunoGen (IMGN) Investor Presentation - Slideshow
|
How Your Smartphone's Video Camera Does Its Magic - ExtremeTech
- Simply stuffing more, better, camera modules into a smartphone doesn't automatically mean better quality video. We dig into some of the behind-the-scenes tech that goes on to give you smooth pans and zooms, and low-noise recordings.
- 06/23/2020
|
Immunic, Inc. to Join Russell 3000® Index
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the company is set to join the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens on June 29, according to a final list of additions accessed on June 19.
- 06/22/2020
|
Triumph Tiger 900 range launched in India, price starts at Rs 13.70 lakh
- New Triumph Tiger 900 is available in three variants in India, with the price ranging between Rs 13.70 lakh (ex-showroom) and Rs 15.50 lakh (ex-showroom).
- 06/19/2020
|
Immunic (NASDAQ:IMUX) Trading 17% Higher
- Immunic (NASDAQ:IMUX) shares traded up 17% during trading on Wednesday . The company traded as high as $13.71 and last traded at $13.58, 609,252 shares changed hands during trading. An increase of 303% from the average session volume of 150,995 shares. The stock had previously closed at $11.61. A number of research analysts recently commented […]
- 06/19/2020
|
'Ndrangheta: commissari, Saint-Pierre terreno per illegalità - Valle d'Aosta
- "Tale situazione di disordine amministrativo costituisce evidentemente terreno fertile per la
pervasione di forme di illegalità e per le mire tentacolari della compagine criminale". (ANSA)
- 06/18/2020
|
Intel : RealSense Depth Camera D455 Twice the Range Better Performance | MarketScreener
|
Intel RealSense Depth Camera D455: Twice the Range, Better Performance | MarketScreener
|
Intel RealSense D455 doubles depth camera accuracy
- Intel has announced a new RealSense model, the latest in its depth-tracking cameras with the promise of extra range and precision. The Intel RealSense Depth Camera D455 looks at first glance like a…
- 06/16/2020
|
Intel's RealSense depth camera brings double the range
- Intel debuted a new RealSense stereo depth camera today, the RealSense D455. This camera improves on prior generations by doubling the range, making it more effective as a sight tool for everything from robots to monitoring hospital rooms.
- 06/16/2020
|
ACEINNA OpenRTK Guidance Module Earns Robotics Innovation Award
- The ACEINNA OpenRTK330L is a low cost, state-of-the-art, high-performance triple-band RTK/GNSS receiver with built-in triple redundant inertial sensors.
- 06/16/2020
|
The Complete Ducati Buying Guide: Every Model, Explained
- Ducati produces a wide range of motorcycles but remains a premium and performance brand. This is your guide to every model they build today.
- 06/15/2020
|
Immunic : Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
|
Immunic, Inc. : Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19 | MarketScreener
|
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced dosing of the first patients in its phase 2, CALVID-1 clinical trial of IMU-838, the company's selective oral DHODH inhibitor, in coronavirus disease 2019 (COVID-19), at several sites in different European countries. Patients will be enrolled at 10 to 35 centers in Germany, the United States and a half dozen European countries.
- 06/15/2020
|
Entro martedì il pagamento Imu, coinvolti 25 milioni - Economia
- Continua il pressing per alleggerire le imposte nell'emergenza (ANSA)
- 06/13/2020
|
Immunic COVID-19 Trial, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:IMUX)
- Immunic is cleared to start a phase 2 trial of its IMU-838 in COVID-19. Soleno receives a setback. Opko records positive data for somatrogon.
- 06/12/2020
|
Inertial Measurement Unit (IMU) Market Size Worth USD 24.91 Billion by 2027; Increasing Application of Artificial Intelligence-powered Devices in Military Operations to Aid Market Growth, Says Fortune Business Insights™
- The global inertial measurement unit market size is projected to reach USD 24.91 billion by 2027, exhibiting a CAGR of 9.22% during the forecast period. Wide
- 06/11/2020
|
Why Immunic (IMUX) Stock Might be a Great Pick
- Immunic (IMUX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 06/11/2020
|
P/E Ratio Insights for Immunic
- In the current market session, Immunic Inc. (NASDAQ: IMUX) is trading at $12.08, after a 5.63% drop. However, over the past month, the stock increased by 18.66%, and in the past year, by 28.78%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 36.59%.The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P; 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Most often, an industry will prevail in a particular phase of a business cycle, than other industries.Immunic Inc. has a lower P/E than the aggregate P/E of 0.25 of the Biotechnology industry. Ideally, one might believe that they might perform worse than its peers, but it's also probable that the stock is undervalued.P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * Insider Buys YayYo's Shares * Insider Buys Donegal Group's Shares * Insider Buys Northern Oil and Gas Shares(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/10/2020
|
Immunic Gets FDA Allowance for Phase II Coronavirus Study
- Immunic (IMUX) gets a FDA allowance to begin a phase II study on its DHODH inhibitor IMU-838 for addressing COVID-19 in the United States. Top-line results on the same are awaited later this year.
- 06/10/2020
|
Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the pricing of its previously announced public offering for the offering of 2,175,000 shares of common stock of the Company at a price to the public of $11.40 per share, for aggregate gross proceeds to the Company of approximately $25 million, before deducting the fees and estimated offering expenses payable by the Company. The offering is expected to close on or about June 12, 2020, subject to customary closing conditions.
- 06/10/2020
|
Immunic, Inc. Announces Proposed Public Offering of Common Stock
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced it has commenced a public offering of shares of its common stock.
- 06/09/2020
|
Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced receipt of regulatory allowance from the U.S. Food and Drug Administration (FDA) to initiate its phase 2, CALVID-1 clinical trial of IMU-838, the company's selective oral DHODH inhibitor, in coronavirus disease 2019 (COVID-19) at centers in the United States.
- 06/09/2020
|
Kabul rejects Pak claims of India using Afghan territory
- The Ashraf Ghani government has rejected Islamabad`s allegation that Afghanistan was allowing its territories to be used by India to destabilize Pakistan.
- 06/06/2020
|
Kabul denounces Pakistan's accusations of TTP using Afghan soil to destabilise region
- Kabul has rejected the allegations by Pakistan foreign ministry about Tehreek-e-Pakistan (TTP) using Afghan territories by a third party to destabilise regional countries, including Pakistan.
- 06/06/2020
|
Benzinga's Top Upgrades, Downgrades For June 5, 2020
- Upgrades * For Kontoor Brands Inc (NYSE: KTB), Susquehanna upgraded the stock from Neutral to Positive. Interestingly, in the first quarter, Kontoor Brands's EPS was $0.27. The stock has a 52-week-high of $43.23 and a 52-week-low of $12.90. Kontoor Brands's stock last closed at $20.23 per share. * Loop Capital changed the rating for Navistar International Corp (NYSE: NAV) from Hold to Buy. For the second quarter, Navistar International had an EPS of ($0.10), compared to year-ago quarter EPS of $1.06. The stock has a 52-week-high of $38.00 and a 52-week-low of $15.01. Navistar International's stock last closed at $27.93 per share. * Wells Fargo upgraded the stock for Sysco Corp (NYSE: SYY) from Equal-Weight to Overweight. For the third quarter, Sysco had an EPS of $0.45, compared to year-ago quarter EPS of $0.79. The stock has a 52-week-high of $85.98 and a 52-week-low of $26.00. Sysco's stock last closed at $58.60 per share. * For Entergy Corp (NYSE: ETR), UBS upgraded the stock from Neutral to Buy. Entergy earned $1.14 in the first quarter, compared to $0.82 in the year-ago quarter. The stock has a 52-week-high of $135.55 and a 52-week-low of $75.19. Entergy's stock last closed at $101.25 per share. * For Hexcel Corp (NYSE: HXL), BMO Capital upgraded the stock from Market Perform to Outperform. In the first quarter, Hexcel showed an EPS of $0.64, compared to $0.84 from the year-ago quarter. The stock has a 52-week-high of $87.00 and a 52-week-low of $24.54. Hexcel's stock last closed at $44.67 per share. * Baird changed the rating for Navistar International Corp (NYSE: NAV) from Neutral to Outperform. For the second quarter, Navistar International had an EPS of ($0.10), compared to year-ago quarter EPS of $1.06. The stock has a 52-week-high of $38.00 and a 52-week-low of $15.01. Navistar International's stock last closed at $27.93 per share. * Evercore ISI Group upgraded the stock for Toll Brothers Inc (NYSE: TOL) from In-Line to Outperform. In the second quarter, Toll Brothers showed an EPS of $0.59, compared to $0.87 from the year-ago quarter. The stock has a 52-week-high of $49.31 and a 52-week-low of $13.28. Toll Brothers's stock last closed at $34.49 per share. * JP Morgan upgraded the stock for Novavax Inc (NASDAQ: NVAX) from Underweight to Neutral. For the first quarter, Novavax had an EPS of ($0.58), compared to year-ago quarter EPS of ($0.11). The stock has a 52-week-high of $61.50 and a 52-week-low of $3.54. Novavax's stock last closed at $44.66 per share. Downgrades * BMO Capital downgraded the stock for eBay Inc (NASDAQ: EBAY) from Outperform to Market Perform. eBay earned $0.77 in the first quarter, compared to $0.67 in the year-ago quarter. The stock has a 52-week-high of $51.88 and a 52-week-low of $26.02. eBay's stock last closed at $49.36 per share. * Goldman Sachs downgraded the stock for Evolent Health Inc (NYSE: EVH) from Buy to Neutral. Evolent Health earned ($0.14) in the first quarter, compared to ($0.31) in the year-ago quarter. The stock has a 52-week-high of $12.01 and a 52-week-low of $3.50. Evolent Health's stock last closed at $6.30 per share. * Raymond James changed the rating for American Airlines Group Inc (NASDAQ: AAL) from Market Perform to Underperform. American Airlines Group earned ($2.65) in the first quarter, compared to $0.52 in the year-ago quarter. The stock has a 52-week-high of $34.99 and a 52-week-low of $8.25. American Airlines Group's stock last closed at $16.74 per share. * Evercore ISI Group downgraded the stock for Builders FirstSource Inc (NASDAQ: BLDR) from Outperform to In-Line. In the first quarter, Builders FirstSource showed an EPS of $0.34, compared to $0.34 from the year-ago quarter. The stock has a 52-week-high of $28.43 and a 52-week-low of $9.00. Builders FirstSource's stock last closed at $22.44 per share. * Evercore ISI Group changed the rating for M.D.C. Holdings Inc (NYSE: MDC) from Outperform to In-Line. M.D.C. Holdings earned $0.56 in the first quarter, compared to $0.64 in the year-ago quarter. The stock has a 52-week-high of $48.99 and a 52-week-low of $15.75. M.D.C. Holdings's stock last closed at $35.48 per share. * For Meritage Homes Corp (NYSE: MTH), Evercore ISI Group downgraded the stock from Outperform to In-Line. Meritage Homes earned $1.83 in the first quarter, compared to $0.65 in the year-ago quarter. The stock has a 52-week-high of $78.43 and a 52-week-low of $25.24. Meritage Homes's stock last closed at $73.65 per share. * RBC Capital changed the rating for Resolute Forest Products Inc (NYSE: RFP) from Outperform to Sector Perform. In the first quarter, Resolute Forest Products showed an EPS of ($0.33), compared to $0.32 from the year-ago quarter. The stock has a 52-week-high of $7.33 and a 52-week-low of $1.14. Resolute Forest Products's stock last closed at $2.31 per share. * RBC Capital downgraded the stock for Rayonier Advanced Materials Inc (NYSE: RYAM) from Outperform to Sector Perform. Rayonier Advanced earned ($0.39) in the first quarter, compared to ($0.52) in the year-ago quarter. The stock has a 52-week-high of $7.34 and a 52-week-low of $0.90. Rayonier Advanced's stock last closed at $3.21 per share. * RBC Capital changed the rating for Domtar Corp (NYSE: UFS) from Outperform to Sector Perform. For the first quarter, Domtar had an EPS of $0.09, compared to year-ago quarter EPS of $1.44. The stock has a 52-week-high of $44.76 and a 52-week-low of $18.40. Domtar's stock last closed at $24.06 per share. * RBC Capital changed the rating for Mercer International Inc (NASDAQ: MERC) from Outperform to Sector Perform. In the first quarter, Mercer International showed an EPS of ($0.05), compared to $0.78 from the year-ago quarter. The stock has a 52-week-high of $15.84 and a 52-week-low of $6.42. Mercer International's stock last closed at $9.77 per share. Initiations Goldman Sachs initiated coverage on Anthem Inc (NYSE: ANTM) with a Neutral rating. The price target for Anthem is set at $340.00. For the first quarter, Anthem had an EPS of $6.48, compared to year-ago quarter EPS of $6.03. The stock has a 52-week-high of $312.48 and a 52-week-low of $171.03. Anthem's stock last closed at $282.09 per share.Goldman Sachs initiated coverage on Humana Inc (NYSE: HUM) with a Buy rating. The price target for Humana is set at $510.00. In the first quarter, Humana showed an EPS of $5.40, compared to $4.48 from the year-ago quarter. The stock has a 52-week-high of $412.70 and a 52-week-low of $208.25. Humana's stock last closed at $392.14 per share.Needham initiated coverage on PTC Inc (NASDAQ: PTC) with a Buy rating. The price target for PTC is set at $100.00. For the second quarter, PTC had an EPS of $0.59, compared to year-ago quarter EPS of $0.22. The stock has a 52-week-high of $93.34 and a 52-week-low of $43.90. PTC's stock last closed at $80.26 per share.With a rating of Hold, HSBC initiated coverage on Coca-Cola European Partners PLC (NYSE: CCEP). The price target is set at $44.00 for Coca-Cola European. The stock has a 52-week-high of $58.94 and a 52-week-low of $28.35. Coca-Cola European's stock last closed at $40.31 per share.BMO Capital initiated coverage on Intercept Pharmaceuticals Inc (NASDAQ: ICPT) with an Outperform rating. The price target for Intercept Pharmaceuticals is set at $107.00. In the first quarter, Intercept Pharmaceuticals showed an EPS of ($2.86), compared to ($3.03) from the year-ago quarter. The stock has a 52-week-high of $125.00 and a 52-week-low of $47.57. Intercept Pharmaceuticals's stock last closed at $76.38 per share.With a rating of Outperform, Wedbush initiated coverage on Immunic Inc (NASDAQ: IMUX). The price target is set at $59.00 for Immunic. Immunic earned ($0.79) in the first quarter, compared to ($0.22) in the year-ago quarter. The stock has a 52-week-high of $19.05 and a 52-week-low of $4.19. Immunic's stock last closed at $11.41 per share.Loop Capital initiated coverage on Super Micro Computer Inc (NASDAQ: SMCI) with a Buy rating. The price target for Super Micro Computer is set at $35.00. The stock has a 52-week-high of $29.27 and a 52-week-low of $15.76. Super Micro Computer's stock last closed at $27.75 per share.With a rating of Outperform, BMO Capital initiated coverage on Viking Therapeutics Inc (NASDAQ: VKTX). The price target is set at $14.00 for Viking Therapeutics. Viking Therapeutics earned ($0.13) in the first quarter, compared to ($0.07) in the year-ago quarter. The stock has a 52-week-high of $8.87 and a 52-week-low of $3.26. Viking Therapeutics's stock last closed at $7.13 per share.With a rating of Hold, Stifel initiated coverage on Cactus Inc (NYSE: WHD). The price target is set at $20.00 for Cactus. For the first quarter, Cactus had an EPS of $0.41, compared to year-ago quarter EPS of $0.49. The stock has a 52-week-high of $35.28 and a 52-week-low of $8.16. Cactus's stock last closed at $21.19 per share.With a rating of Buy, Rosenblatt initiated coverage on Qualcomm Inc (NASDAQ: QCOM). The price target is set at $105.00 for Qualcomm. In the second quarter, Qualcomm showed an EPS of $0.88, compared to $0.77 from the year-ago quarter. The stock has a 52-week-high of $96.17 and a 52-week-low of $58.00. Qualcomm's stock last closed at $86.04 per share.Rosenblatt initiated coverage on ON Semiconductor Corp (NASDAQ: ON) with a Buy rating. The price target for ON Semiconductor is set at $22.00. ON Semiconductor earned $0.10 in the first quarter, compared to $0.43 in the year-ago quarter. The stock has a 52-week-high of $25.92 and a 52-week-low of $8.17. ON Semiconductor's stock last closed at $18.98 per share.Cowen & Co. initiated coverage on Livongo Health Inc (NASDAQ: LVGO) with an Outperform rating. The price target for Livongo Health is set at $69.00. Interestingly, in the first quarter, Livongo Health's EPS was $0.03.
- 06/05/2020
|
Biopharmaceutical Contract Manufacturing(BCMO) Market Size 2020 Explosive Factors of Revenue By Industry Statistics, Progression Status, Emerging Demands, Recent Trends, Business Opportunity, Major Distributors Analysis To 2025
- May 31, 2020 (The Expresswire) --
Global “Biopharmaceutical Contract Manufacturing(BCMO) Market” is a comprehensive research that provides information...
- 05/31/2020
|
Immunic, Inc. to Participate in Investor and Industry Conferences in June
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's participation in the following investor and industry conferences in June:
- 05/29/2020
|
COVID-19 Drug and Vaccine Pipeline Status Report - Research; Pre-Clinical; Phase 1, 2 & 3 Drug Candidates - ResearchAndMarkets.com
|
A Black administrator, a white campus, and social change
- One of your neighbors posted in Neighbor News. Click through to read what they have to say. (The views expressed in this post are the author’s own.)
- 05/20/2020
|
Urban Outfitters, Inc. (URBN) CEO Richard Hayne on Q1 2021 Results - Earnings Call Transcript
- Urban Outfitters, Inc. (NASDAQ:URBN) Q1 2021 Earnings Conference Call May 19, 2020 05:15 p.m. ET Company Representatives Richard Hayne - Chief Executive Officer
- 05/20/2020
|
Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that it will host a virtual R&D; Day today, May 19, 2020, from 9:00 am to 1:00 pm ET. Immunic's management and invited key opinion leaders, specializing in multiple sclerosis and inflammatory bowel disease, will discuss today's treatment options for, and the unmet medical needs of, chronic inflammatory and autoimmune diseases, as well as clinical progress of Immunic's selective oral immunology programs and their potential advantages over the current treatment landscape. Management will also discuss the company's coronavirus disease 2019 (COVID-19) program.
- 05/19/2020
|
Corporate News for May 15, 2020
- Companies In The News Are: APDN, CSCO, IMUX, VRTU
- 05/15/2020
|
A Peek Into Immunic's P/E Ratio
- In the current session, Immunic Inc. (NASDAQ: IMUX) is trading at $11.44, after a 12.35% spike. Over the past month, the stock increased by 48.93%, and in the past year, by 12.58%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently down from its 52 week high by 39.96%.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.Most often, an industry will prevail in a particular phase of a business cycle, than other industries.Immunic has a lower P/E than the aggregate P/E of 6.49 of the biotechnology industry. Ideally, one might believe that they might perform worse than its peers, but it's also probable that the stock is undervalued.There are many limitations to price to earnings ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.See more from Benzinga * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session * 17 Healthcare Stocks Moving In Wednesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/14/2020
|
Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has received first regulatory approval from Germany's BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) to initiate a phase 2 clinical trial of its selective oral DHODH inhibitor, IMU-838, in coronavirus disease 2019 (COVID-19). The CALVID-1 study is a prospective, multicenter, randomized, placebo-controlled, double-blind phase 2 clinical trial in approximately 230 patients with moderate COVID-19, designed to evaluate efficacy, safety and tolerability of IMU-838. Dosing of the first patient is expected to occur later this month. Top-line data is expected to be available later this year.
- 05/13/2020
|
Ulcerative Colitis Industry Review and Outlook 2016-2024 - ResearchAndMarkets.com
|
Immunic, Inc. Reports First Quarter 2020 Financial Results and Highlights Recent Activity
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended March 31, 2020 and highlighted recent activity.
- 05/08/2020
|
Immunic, Inc. Announces Pricing of $15 Million Financing
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has entered into securities purchase agreements with certain institutional investors, led by Altium Capital, providing for the purchase and sale of 1,764,706 shares of common stock at a price of $8.50 per share in a registered direct offering.
- 04/23/2020
|
CMG, CLDX among premarket gainers
- SAExploration Holdings (NASDAQ:SAEX) +177% on $27M new project in Greece.B.O.S. Better Online Solutions (NASDAQ:BOSC) +56% on $1M order.The Peck Company Holdings (NASDAQ:PECK) +51% on partnership with
- 04/22/2020
|
Fly Intel: Pre-market Movers IMUX;MNK;EXPE;T;DAL;KMB;DGX;TER;CMG;BIIB;NFLX;IBKR;IRBT
- Fly Intel: Pre-market Movers IMUX MNK EXPE T DAL KMB DGX TER CMG BIIB NFLX IBKR IRBT
- 04/22/2020
|
The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Arvinas Inc (NASDAQ: ARVN) * Exelixis, Inc. (NASDAQ: EXEL
- 04/22/2020
|
9 Stocks Moving In Tuesday's After-Hours Session
- Gainers
Netflix (NASDAQ: NFLX) shares are trading higher after the company reported better-than-expected Q1 sales results. The company reported Q1 global streaming subs of...
- 04/21/2020
|
Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today reported that its lead asset, IMU-838, a selective oral DHODH inhibitor, has successfully demonstrated preclinical activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). More specifically, IMU-838 was observed to inhibit replication of clinical isolates of SARS-CoV-2 associated with coronavirus disease 2019 (COVID-19). In cellular assays, IMU-838 demonstrated this antiviral activity at concentrations which are well below the blood concentrations associated with IMU-838 dosing regimens studied in ongoing and previous clinical trials. These positive results have encouraged Immunic to prepare a clinical development program for IMU-838 as a potential treatment option for patients with COVID-19 and potential other, future viral pandemics.
- 04/21/2020
|
A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings
- Pre-open movers
U.S. stock futures traded lower in early pre-market trade, ahead of earnings from Halliburton Company (NYSE: HAL) and International Business Machines Corporation...
- 04/20/2020
|
5 Stocks To Watch For April 20, 2020
- Some of the stocks that may grab investor focus today are:
Wall Street expects Halliburton Company (NYSE: HAL) to report quarterly earnings at $0.24 per share on revenue of $5....
- 04/20/2020
|
Immunic, Inc. Announces Changes to Executive Team
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced a series of changes to its Executive Team, including the departure of Chief Financial Officer, Sanjay S. Patel, CFA, who has resigned to pursue opportunities in the nonprofit sector.
- 04/17/2020
|
Oculus Firmware Reveals New Touch Controllers, Referencing Improvements To Tracking, Finger Sensing, Haptics
- ICYMI: a 'Jedi' Touch controller with a new accelerometer was found in Oculus Quest's firmware!
- 04/16/2020
|
BUZZ-U.S. STOCKS ON THE MOVE-J&J, Apple, Roku, Tesla, U.S. airlines
- * Eikon search string for individual stock moves:
- 04/14/2020
|
Suzuki V-Strom: Vom Entlein zum stolzen Schwan - Blick
- Sieben Jahre ist es her, seit Suzuki die V-Strom zuletzt umfassend überarbeitet hat. Nun startet die V-Strom mit komplett neuer Optik und wird so vom Entlein zum stolzen Schwan.
- 04/06/2020
|
Multi-Agent Seasonal Dataset For Autonomous Car Development by Ford
- Recently, researchers from the multinational automaker, Ford launched a challenging multi-agent seasonal dataset for autonomous cars.
- 03/23/2020
|
Contrasting Immunic (NASDAQ:IMUX) and Kiniksa Pharmaceuticals (NASDAQ:KNSA)
- Immunic (NASDAQ:IMUX) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability. Insider & Institutional Ownership 21.2% of Immunic shares are held by institutional investors. Comparatively, 29.1% of […]
- 03/23/2020
|
Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the year ended December 31, 2019 and highlighted recent achievements.
- 03/16/2020
|
Urban Outfitters Inc (NASDAQ: URBN) Q4 2020 Earnings Transcript | AlphaStreet
- Good day, ladies and gentlemen, and welcome to the Urban Outfitters Incorporated Fourth Quarter Fiscal 2020 Earnings Call.
- 03/04/2020
|
Italian Travel and Tourism Agents plead for help with COVID-19
- The president of the Federation of Italian Travel and Tourism Agents (FIAVET) pleaded: “Tourism is in full crisis because of COVID-19.
- 02/27/2020
|
Merantix: Incubating AI Ideas Into AI Startups
- We've been researching and writing about disruptive technologies for over a decade now, and every day our inbox fills up with all kinds of emails. While most inquiries come from PR firms and link whores, the remainder runs the gamut: from Catherine in Texas who wants us to help her rent a car, to the schizophrenics that email us about the voices they keep hearing. As you would expect, we also get a fair number of what salespeople call 'leads.' These represent companies that are looking to solve a problem using AI but don't know where to start - like the large tire company in
- 02/21/2020
|
Immunic, Inc. to Participate in Scientific and Investor Conferences in February
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's participation in the following scientific and investor conferences in February:
- 02/11/2020
|
Top 10 Popular Datasets For Autonomous Driving Projects
- Since a few years, organisations have been investing heavily in the autonomous driving space. The reason behind this spending is expected
- 01/17/2020
|
Lithium shares continue to rally: Aus shares close 0.9% higher
- 14 Jan 2020 - It’s been a positive day of trade for the Australian share market closing 0.9 per cent higher. Kangaroo Island Plantation Timbers (ASX:KPT) report further damage.
- 01/14/2020
|
Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that its subsidiary, Immunic AG, under the terms of its existing option and license agreement with Daiichi Sankyo Co., Ltd. (hereinafter, Daiichi Sankyo), has exercised its exclusive global option to license a group of compounds, designated by Immunic as IMU-856. The company intends to begin phase 1 clinical studies for this program in the first half of 2020. IMU-856 is an orally available, small molecule modulator that targets a yet undisclosed protein which serves as a transcriptional regulator of the intestinal barrier function. As such, IMU-856 represents a new and potentially disruptive approach for the treatment of intestinal diseases with the potential to restore the intestinal barrier function while maintaining immunocompetency.
- 01/08/2020
|
Immunic, Inc. to Present Data on IMU-856, for the First Time, at the Crohn's and Colitis Foundation's IBD Innovate Conference
- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present data on IMU-856, for the first time, at today's IBD Innovate: Product Development for Crohn's and Colitis conference in New York, hosted by the Crohn's and Colitis Foundation.
- 12/04/2019
|
Imugene Limited (ASX:IMU) completes OV acquisition: Aus shares 0.6% lower at noon
- 18 Nov 2019 - Australian share market dipped on open despite ‘constructive discussions’ regarding the phase-one China and US trade deal between negotiators. Imugene Limited (ASX:IMU) has completed the acquisition of its Oncolytic Virus.
- 11/18/2019
|
Intel’s New RealSense Camera Adds Positional Tracking To Any Headset For $199
- Intel today announced a stereo camera module which performs positional tracking. The RealSense Tracking Camera T265 can be preordered today for $199. It’s intended for robotics, drones, and head mounted displays. Unlike all other RealSense products, the T265 is not a depth sensor. It contains two cameras with fisheye lenses and global shutter sensors. It…
- 01/24/2019
|
New Low-Power Chip Will Help Miniature Drones Navigate
- The new computer chip, named “Navion” is just 20 square millimeters — about the size of a LEGO minifigure’s footprint — and consumes just 24 milliwatts of power, or about 1 one-thousandth the energy required to power a lightbulb.
- 06/20/2018
|
With ARCore, Google brings augmented reality to Android without needing special hardware - 9to5Google
- Since Apple announced ARKit in June, the three-year-old Tango has been cited as the less successful mobile AR competitor due to devices requiring special lenses and sensors. However, Google today unveiled its real competing platform for augmented reality on existing Android devices without the need for any extra hardware. ARCore is built on Tango, with …
- 08/29/2017
|
DJI Phantom 4 Review: The first drone for everyone
- The drone takes off, hovering a few feet off the ground. I guide it up to about 12 feet with the throttle on the remote control. Then my three year old son takes over. He taps the screen on an iPad...
- 03/10/2016
|
Now that the dust has settled after GDC, here’s what we know about the Vive VR Lighthouse Tracking System
- During the Mobile World Congress in Barcelona this year, HTC and Valve announced their flagship virtual reality headset called Vive VR. A few days later, demonstrations of the input tracking solution were shown to exclusive members of the press as well as developers in the VR community at the Game Developer Conference (GDC) in San Francisco.…
- 03/09/2015
|
Mechanical Data
- We accept .gif and .jpeg files, and Flash files for our website. IAB (Internet Advertising Bureau) guidelines recommend that a.gif alternative is provided to Flash. Some devices, notably the Apple …
- 05/14/2010
|
